-
公开(公告)号：US20040162288A1
公开(公告)日：2004-08-19
申请号：US10712900
申请日：2003-11-13
Applicant: Cell Therapeutics, Inc.
Inventor： Baoqing Gong , John Tulinsky , Lynn Bonham , J. Peter Klein , Robert E. Finney , David M. Hollenback , Scott A. Shaffer , Norina M. Tang , Thayer H. White , David W. Leung
IPC: A61K031/5377 , A61K031/53
CPC classification number: C07D251/70 , C07D251/50 , C07D251/52 , C07D251/54 , C07D251/58
Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase null (LPAAT-null) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-null activity.
Abstract translation: 本发明涉及三嗪及其用于抑制溶血磷脂酰基转移酶β（LPAAT-β）活性的用途。 本发明还涉及使用所述三嗪治疗癌症的方法。 本发明还涉及用于筛选LPAAT-β活性的方法。
-
公开(公告)号：US20020103195A1
公开(公告)日：2002-08-01
申请号：US09984888
申请日：2001-10-31
Applicant: CELL THERAPEUTICS,INC.
Inventor： Lynn Bonham , J. Peter Klein , Robert E. Finney , David M. Hollenback , Scott A. Shaffer , Norina M. Tang , Thayer H. White , David W. Leung
IPC: A61K031/5377 , A61K031/53 , C07D413/14 , C07D43/14
CPC classification number: C07D251/70 , C07D251/50 , C07D251/52 , C07D251/54 , C07D251/58
Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase null (LPAAT-null) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-null activity.
Abstract translation: 本发明涉及三嗪及其用于抑制溶血磷脂酰基转移酶β（LPAAT-β）活性的用途。 本发明还涉及使用所述三嗪治疗癌症的方法。 本发明还涉及用于筛选LPAAT-β活性的方法。
-
公开(公告)号：US20030100557A1
公开(公告)日：2003-05-29
申请号：US10236084
申请日：2002-09-06
Applicant: Cell Therapeutics, Inc.
Inventor： Robert Finney , David Leung , J. Peter Klein , David M. Hollenback , Lynn Bonham , Scott A. Shaffer , Norina M. Tang , Thayer H. White , John Tulinsky , Baoqing Gong
IPC: A61K031/5377 , A61K031/53 , C07D413/14 , C07D413/04 , C07D43/02
CPC classification number: C07D251/70 , C07D251/50 , C07D251/52 , C07D251/54 , C07D251/58
Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase null (LPAAT-null) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-null activity.
-
公开(公告)号：US20020107269A1
公开(公告)日：2002-08-08
申请号：US09984889
申请日：2001-10-31
Applicant: CELL THERAPEUTICS, INC.
Inventor： Lynn Bonham , J. Peter Klein , Robert E. Finney , David M. Hollenback , Scott A. Shaffer , Norina M. Tang , Thayer H. White , David W. Leung
IPC: A61K031/428 , A61K031/423 , A61K031/4184 , C07D277/60 , C07D263/56
CPC classification number: C07D263/57 , C07D235/18 , C07D277/66
Abstract: The invention relates to benzoxazoles and the use thereof to inhibit lysophosphatidic acid acyltransferase null (LPAAT-null) activity. The invention further relates to methods of treating cancer using said benzoxazoles. The invention also relates to methods for screening for LPAAT-null activity.
Abstract translation: 本发明涉及苯并恶唑及其用于抑制溶血磷脂酰基转移酶β（LPAAT-β）活性的用途。 本发明还涉及使用所述苯并恶唑治疗癌症的方法。 本发明还涉及用于筛选LPAAT-β活性的方法。
-
-
-
Search Results
4
records
(took 0.032 seconds)
